Personalized Care: How Do NSCLC Treatment Modifications and Patient-Specific Factors Impact Health Outcomes?

Balancing Efficacy and Quality of Life

• Approaches to managing toxicity:
• Dose adjustments within recommended ranges

• Temporary holds until toxicity resolves

• Rotation to alternative agents within the same class
• EGFR tyrosine kinase inhibitor selection factors:
• Consider patient comorbidities and concomitant medications

• Baseline interstitial lung disease: may favor erlotinib over osimertinib

• Cardiac comorbidities (low ejection fraction, QTc prolongation): may favor erlotinib

• Poor performance status: minimize agents that could contribute to toxicities

• Patient preferences and lifestyle considerations significantly impact adherence